Our Team


TAT11 Co-Chairs

BobHolmes.jpg

Robert (Bob) Holmes, PhD

Chief Scientist, Canadian Nuclear Laboratories, Chalk River, Ontario

Dr. Bob Holmes began his career at Fisons Pharmaceuticals, developing compounds for treating iron deficient anaemia. In 1972 he went to the University of Manchester, Institute of Science and Technology where he studied transition metal complexes of a stable free radical. In 1977 he carried out post-doctoral studies in free radical chemistry at the University of York.

In 1977 Bob moved to British Nuclear Fuels (BNFL) at Sellafield, UK, where he carried out development of the head-end of the Thermal Oxide Reprocessing Plant. In 1992 Bob was invited to run the BNFL Corporate Laboratory at Springfields in the UK and was instrumental in setting up a US subsidiary of BNFL, BNFL Inc. In 1996 Bob moved back to Sellafield to coordinate waste management R&D and was concurrently Technical Director of BNFL’s Engineering, Waste Management  and Decommissioning Division. He was given the additional role of Chief Scientist which included performing due diligence on major projects and acquisitions. The most significant acquisition was Westinghouse, whilst major projects included waste management plant at Sellafield and three multi-billion dollar jobs in the USA.

In 1999 Bob moved to BNFL Inc where he was the Chief Technology Officer and Technical Manager of  the Advanced Mixed Waste Treatment Plant, whilst retaining his role as BNFL Group Chief Scientist.

In 2006 BNFL Inc was acquired by EnergySolutions where Bob continued in his role of Chief Scientist. After leaving EnergySolutions Bob led the technical aspects of two successful bids, one of which being the CNEA bid to run the AECL facilities.

Honours and other activities include:

  • Awarded a Dr of Science by DeMontfort University in the UK
  • Professor at Queens University Belfast in the Department of Chemistry
  • Associate Professor at the University of Idaho
  • Associate of Wolfson College University of Oxford, UK
  • Ran the UK, Minatom program in the former Soviet Union
  • Chair of the Waste Technology Advisory Committee for the IAEA
  • Served on advisory boards for the Daresbury Lab, an Integrated Research Facility run by the Universities of Liverpool and Manchester, the QUESTOR Center in Belfast, the UK High Level Waste review committee and served on the technical board for UK NIREX
paul schaffer.jpg

Paul Schaffer, PhD

Associate Laboratory Director, Life Sciences TRIUMF, Vancouver, British Columbia, 

Dr. Paul Schaffer graduated from the University of British Columbia in 1998 with a BSc in chemistry and biochemistry. From there he began his MSc in chemistry at McMaster University and transferred directly in the Ph.D. program two years later. His doctoral work focused on the design and synthesis of technetium and rhenium chelates as potential new radioimaging or radiotherapy agents. After successfully completing his doctoral thesis in 2003, Dr. Schaffer stayed at McMaster for a brief period of post doctoral work and then settled as a Research Scientist at the McMaster Nuclear Reactor (MNR). In this role, Dr. Schaffer was responsible for demonstrating medical applications for isotopes produced at MNR. In 2006, Dr. Schaffer entered the private sector as a Lead Scientist at General Electric Global Research in upstate NY. There, he was responsible for developing novel radiotracers for GE Healthcare. In the latter half of 2009, Dr. Schaffer returned to Canada to accept his new role as Deputy Head, and is now Head of the Life Sciences program at TRIUMF. He is responsible for maintaining TRIUMF’s medical isotope and radiotracer production programs in support of neurological and oncology research. He also leads a research program geared toward developing novel radiopharmaceutical compounds for imaging and diagnosis and treatment of disease. 

For his leadership efforts, Dr. Schaffer was recognized by Business in Vancouver as one of British Columbia’s 2013 Top Forty under 40 individuals; recognizing him as an effective researcher with an ability to create teams that produce high-impact results on short time scales. He was also recently awarded the 2015 NSERC Brockhouse Prize for Interdisciplinary Research.

Dr. Schaffer continues to re-define the TRIUMF Life Sciences program by focusing on its core competencies to deliver specific outcomes, and continues to connect the TRIUMF program with industrial and commercial interests. Dr. Schaffer is a leader, an entrepreneur and one of British Columbia's most promising talents.


Clinical Committee Co-Chairs

Scientific Committee Co-Chairs

  Dr. Fred Saad, MD FRCS, Professor and Chairman of Urology and Director of G-U Oncology at the University of Montreal Hospital Centers Canada

Dr. Fred Saad, MD FRCS, Professor and Chairman of Urology and Director of G-U Oncology at the University of Montreal Hospital Centers Canada

  Professor Wim Oyen, Professor of Nuclear Medicine and Molecular Imaging and Team Leader in Translational Molecular Imaging at The Institute of Cancer Research, England

Professor Wim Oyen, Professor of Nuclear Medicine and Molecular Imaging and Team Leader in Translational Molecular Imaging at The Institute of Cancer Research, England

  Valery Radchenko, PhD, Scientist, TRIUMF, Canada

Valery Radchenko, PhD, Scientist, TRIUMF, Canada

  Patrick Causey, PhD, Research Scientist, Canadian Nuclear Laboratories, Canada

Patrick Causey, PhD, Research Scientist, Canadian Nuclear Laboratories, Canada